SLXN SILEXION THERAPEUTICS CORP

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit

Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.  

The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic, cardiovascular, and oncological diseases. Silexion is developing SIL204, a next-generation siRNA therapy designed to silence mutated KRAS oncogenes - the most common oncogenic driver in human cancers. SIL204 is planned to enter a Phase 2/3 clinical study program in locally advanced pancreatic cancer in mid 2026.

Silexion management will host one-on-one meetings during the summit. Interested parties should contact the Company’s Investor Relations representatives who can arrange such meetings.

Silexion is pleased to be an official partner of the RNAi-Based Therapeutics Summit for 2026.



About Silexion Therapuetics

Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit:

Company Contact:

Silexion Therapeutics Corp

Ms. Mirit Horenshtein Hadar, CFO

Investor Relations

Arx Investor Relations

North American Equities Desk



EN
21/01/2026

Underlying

SLXNSILEXION THERAPEUTICS CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SILEXION THERAPEUTICS CORP

 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Sum...

Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management, including CEO Ilan Hadar, will attend the 7th RNAi-Based Therapeutics Summit, taking place January 27-29 in Boston, MA.   The 7th RNAi-Based Therapeutics Summit is the industry's premier forum inviting drug developers to discuss RNA-based therapeutics for neurological, metabolic, cardiovascular, an...

January 21, 2026 1 EN
 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting...

Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026 SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company’s Platform Seeks to Address an Estimated $30+ Billion Global KRAS-Driven Cancer Market with Pan-KRAS Therapeutic Platform Initiation of Phase 2/3 Clinical Trial in LAPC Planned for H1 2026 Following Positive Regulatory Feedback and Successful Toxicology Studies Grand Cayman, Cayman Island...

January 6, 2026 1 EN
 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial...

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed Application follows recent successful toxicology studies, positive German regulatory feedback, and strong preclinical data demonstrating up to 99.7% cancer cell inhibition Regulatory filings in Germany and the EU are planned for Q1 2026, with U.S. expansion anticipated following the safety run-in Grand Cayman, Cayma...

December 16, 2025 1 EN
 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics Receives Positive Feedback from German Health Au...

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the end of Q4 2025 and in Germany during Q1 2026 GRAND CAYMAN, Cayman Islands, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company developing RNA interference (RNAi) ...

December 2, 2025 1 EN
 PRESS RELEASE
Free
SLXN SILEXION THERAP...

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual...

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21). Presentation details:Type: Company presentationDate: December 3, 2025Time: 2:30 – 2:55pm ETSpeakers: Ilan Hadar, Chief Executive Officer and Miri...

November 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch